197 related articles for article (PubMed ID: 18799592)
1. Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist.
Mukherjee R; Locke KT; Miao B; Meyers D; Monshizadegan H; Zhang R; Search D; Grimm D; Flynn M; O'Malley KM; Zhang L; Li J; Shi Y; Kennedy LJ; Blanar M; Cheng PT; Tino J; Srivastava RA
J Pharmacol Exp Ther; 2008 Dec; 327(3):716-26. PubMed ID: 18799592
[TBL] [Abstract][Full Text] [Related]
2. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo.
Beyer TP; Schmidt RJ; Foxworthy P; Zhang Y; Dai J; Bensch WR; Kauffman RF; Gao H; Ryan TP; Jiang XC; Karathanasis SK; Eacho PI; Cao G
J Pharmacol Exp Ther; 2004 Jun; 309(3):861-8. PubMed ID: 14960661
[TBL] [Abstract][Full Text] [Related]
3. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
4. Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor, and liver X receptor in mouse liver.
Anderson SP; Dunn C; Laughter A; Yoon L; Swanson C; Stulnig TM; Steffensen KR; Chandraratna RA; Gustafsson JA; Corton JC
Mol Pharmacol; 2004 Dec; 66(6):1440-52. PubMed ID: 15371561
[TBL] [Abstract][Full Text] [Related]
5. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
6. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.
Peng D; Hiipakka RA; Dai Q; Guo J; Reardon CA; Getz GS; Liao S
J Pharmacol Exp Ther; 2008 Nov; 327(2):332-42. PubMed ID: 18723776
[TBL] [Abstract][Full Text] [Related]
7. Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo.
Guo L; Hu WR; Lian JH; Ji W; Deng T; Qian M; Gong BQ
Eur J Pharmacol; 2006 Dec; 551(1-3):80-6. PubMed ID: 17026988
[TBL] [Abstract][Full Text] [Related]
8. Intestine-specific regulation of PPARalpha gene transcription by liver X receptors.
Colin S; Bourguignon E; Boullay AB; Tousaint JJ; Huet S; Caira F; Staels B; Lestavel S; Lobaccaro JM; Delerive P
Endocrinology; 2008 Oct; 149(10):5128-35. PubMed ID: 18566121
[TBL] [Abstract][Full Text] [Related]
9. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice.
Kuwabara K; Murakami K; Todo M; Aoki T; Asaki T; Murai M; Yano J
J Pharmacol Exp Ther; 2004 Jun; 309(3):970-7. PubMed ID: 14982965
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor-α activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway.
Nakaya K; Tohyama J; Naik SU; Tanigawa H; MacPhee C; Billheimer JT; Rader DJ
Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1276-82. PubMed ID: 21441141
[TBL] [Abstract][Full Text] [Related]
11. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
[TBL] [Abstract][Full Text] [Related]
12. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
[TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.
Li AC; Binder CJ; Gutierrez A; Brown KK; Plotkin CR; Pattison JW; Valledor AF; Davis RA; Willson TM; Witztum JL; Palinski W; Glass CK
J Clin Invest; 2004 Dec; 114(11):1564-76. PubMed ID: 15578089
[TBL] [Abstract][Full Text] [Related]
15. Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice.
Takei K; Nakagawa Y; Wang Y; Han SI; Satoh A; Sekiya M; Matsuzaka T; Shimano H
J Pharmacol Sci; 2017 Apr; 133(4):214-222. PubMed ID: 28366492
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4.
Sanguino E; Roglans N; Alegret M; Sánchez RM; Vázquez-Carrera M; Laguna JC
Br J Pharmacol; 2005 Aug; 145(7):853-61. PubMed ID: 15912134
[TBL] [Abstract][Full Text] [Related]
17. Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).
Li J; Kennedy LJ; Shi Y; Tao S; Ye XY; Chen SY; Wang Y; Hernández AS; Wang W; Devasthale PV; Chen S; Lai Z; Zhang H; Wu S; Smirk RA; Bolton SA; Ryono DE; Zhang H; Lim NK; Chen BC; Locke KT; O'Malley KM; Zhang L; Srivastava RA; Miao B; Meyers DS; Monshizadegan H; Search D; Grimm D; Zhang R; Harrity T; Kunselman LK; Cap M; Kadiyala P; Hosagrahara V; Zhang L; Xu C; Li YX; Muckelbauer JK; Chang C; An Y; Krystek SR; Blanar MA; Zahler R; Mukherjee R; Cheng PT; Tino JA
J Med Chem; 2010 Apr; 53(7):2854-64. PubMed ID: 20218621
[TBL] [Abstract][Full Text] [Related]
18. Synthetic LXR agonists increase LDL in CETP species.
Groot PH; Pearce NJ; Yates JW; Stocker C; Sauermelch C; Doe CP; Willette RN; Olzinski A; Peters T; d'Epagnier D; Morasco KO; Krawiec JA; Webb CL; Aravindhan K; Jucker B; Burgert M; Ma C; Marino JP; Collins JL; Macphee CH; Thompson SK; Jaye M
J Lipid Res; 2005 Oct; 46(10):2182-91. PubMed ID: 16024916
[TBL] [Abstract][Full Text] [Related]
19. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.
Hambruch E; Miyazaki-Anzai S; Hahn U; Matysik S; Boettcher A; Perović-Ottstadt S; Schlüter T; Kinzel O; Krol HD; Deuschle U; Burnet M; Levi M; Schmitz G; Miyazaki M; Kremoser C
J Pharmacol Exp Ther; 2012 Dec; 343(3):556-67. PubMed ID: 22918042
[TBL] [Abstract][Full Text] [Related]
20. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice.
Peters JM; Hennuyer N; Staels B; Fruchart JC; Fievet C; Gonzalez FJ; Auwerx J
J Biol Chem; 1997 Oct; 272(43):27307-12. PubMed ID: 9341179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
